keyword
MENU ▼
Read by QxMD icon Read
search

deb-tace hcc

keyword
https://www.readbyqxmd.com/read/28500458/occurrence-of-vascular-lake-phenomenon-as-a-predictor-of-improved-tumor-response-in-hcc-patients-that-underwent-deb-tace
#1
Rafael Noronha Cavalcante, Felipe Nasser, Joaquim M Motta-Leal-Filho, Breno B Affonso, Francisco L Galastri, Bruna De Fina, Rodrigo G Garcia, Nelson Wolosker
PURPOSE: To evaluate incidence and predictive factors for the vascular lake phenomenon (VLP), as well as to compare local and overall tumor response in patients with and without VLP induced during DEB-TACE for HCC. METHODS: A total of 200 consecutive patients with 323 HCC nodules underwent first-session DEB-TACE from 2011 to 2014. Patients were divided in two groups, according to the presence of the VLP during DEB-TACE. Pre- and post-treatment imaging studies (CT or MRI) were performed...
May 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#2
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28442142/predictors-of-therapeutic-effect-of-transarterial-chemoembolisation-using-drug-eluting-beads-for-hepatocellular-carcinoma
#3
Y Asayama, D Okamoto, Y Ushijima, A Nishie, K Ishigami, Y Takayama, N Fujita, H Honda
AIMS: To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1-4 months after the procedure...
April 22, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28436630/-clinical-investigation-on-transarterial-chemoembolization-with-indigenous-drug-eluting-beads-in-treatment-of-unresectable-hepatocellular-carcinoma
#4
Gang Chen, Ding Zhang, Yacao Ying, Zhifeng Wang, Wei Tao, Hao Zhu, Jingfeng Zhang, Zhiyi Peng
Objective: To evaluate the efficacy and safety of drug-eluding beads transarterial chemoembolization (DEB-TACE) in treatment of unrecectable hepatocellular carcinoma (HCC). Methods: The clinical data of 42 consecutive HCC patients undergoing TACE were retrospectively analyzed, including 20 cases received conventional TACE (cTACE group) and 22 cases received TACE with epirubicine-loaded microspheres (CalliSpheres (®)) (DEB-TACE group). MRI scans were performed 1 week before and 1, 3 and 6 months after initial therapy...
January 25, 2017: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#5
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28228906/histological-assessment-of-the-efficacy-of-drug-eluting-beads-in-portal-tumor-thrombosis-of-hepatocellular-carcinoma
#6
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#7
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28166821/deb-tace-for-intermediate-and-advanced-hcc-initial-experience-in-a-brazilian-cancer-center
#8
Jose Hugo Mendes Luz, Paula M Luz, Henrique S Martin, Hugo R Gouveia, Raphal Braz Levigard, Felipe Diniz Nogueira, Bernardo Caetano Rodrigues, Tiago Nepomuceno de Miranda, Marcelo Henrique Mamede
BACKGROUND: According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arterial administration. This type of transarterial chemoembolization approach appears to provide at least equivalent effectiveness with less toxicity. METHODS: This is a prospective, single-center study, which evaluated 21 patients with intermediate and advanced hepatocellular carcinoma who underwent transarterial chemoembolization with drug-eluting microspheres...
February 6, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/27834009/predicting-outcomes-after-chemo-embolization-in-patients-with-advanced-stage-hepatocellular-carcinoma-an-evaluation-of-different-radiologic-response-criteria
#9
Andrew J Gunn, Rahul A Sheth, Brandon Luber, Minh-Huy Huynh, Niranjan R Rachamreddy, Sanjeeva P Kalva
PURPOSE: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with advanced-stage (BCLC C) hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Hospital records from 2005 to 2011 were retrospectively reviewed. Non-infiltrative lesions were measured at baseline and on follow-up scans after DEB-TACE according to various common radiologic response criteria, including guidelines of the World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), the European Association for the Study of the Liver (EASL), and modified RECIST (mRECIST)...
January 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27824665/tumor-enhancement-and-heterogeneity-are-associated-with-treatment-response-to-drug-eluting-bead-chemoembolization-for-hepatocellular-carcinoma
#10
Stephen P Reis, Patrick D Sutphin, Amit G Singal, Richard Grzybowski, Stephen Fisher, Christopher Ball, Yin Xi, Simer Grewal, Sanjeeva P Kalva
PURPOSE: Treatment response to drug-eluting bead chemoembolization (DEB-TACE) is well established for patients with hepatocellular carcinoma (HCC); however, few studies have evaluated tumor imaging characteristics associated with treatment responses. The aim of our study was to identify imaging characteristics associated with treatment responses and overall survival after DEB-TACE of HCC. METHODS: This is a retrospective cohort study of 33 tumors in 32 patients who underwent DEB-TACE for inoperable HCC in a single, large academic medical center...
March 2017: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/27733318/nine-year-experience-of-doxorubicin-eluting-beads-chemoembolization-for-hepatocellular-carcinoma
#11
Alvin Ho-Kwan Cheung, Colin Siu-Chi Lam, Henry Shiu-Cheung Tam, Tan-To Cheung, Roberta Pang, Ronnie Tung-Ping Poon
BACKGROUND: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efficacy and survival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment. METHODS: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of computed tomography and serum alpha-fetoprotein (AFP)...
October 2016: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/27705924/a-mixed-analysis-comparing-nine-minimally-invasive-surgeries-for-unresectable-hepatocellular-carcinoma-patients
#12
Ran Tao, Xiaodan Li, Ruizhi Ran, Zhihua Xiao, Hongyue Zhang, Hongyan Kong, Qiqin Song, Yu Huang, Likui Wang, Jiaquan Huang
Hepatocellular carcinoma (HCC) is usually managed by the transcatheter arterial chemoembolization (TACE). However, this technique has been challenged since severe complications have been observed in clinical practices. As a result, clinicians have started to seek other minimally invasive surgeries with equivalent efficacy. The corresponding surgeries were assessed by the five outcomes: complete response (CR), partial response (PR), stable disease (SD), progression disease (PD) and objective response rate (ORR)...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/27644658/conventional-versus-doxorubicin-eluting-beads-transarterial-chemoembolization-for-unresectable-hepatocellular-carcinoma-a-tertiary-medical-centre-experience-in-malaysia
#13
F Abdul Rahman, J Naidu, C S Ngiu, Y Yaakob, Z Mohamed, H Othman, R Jarmin, M H Elias, N Abdul Hamid, N Mohd Mokhtar, Ra Raja Ali
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is frequently diagnosed at an advanced stage. Transarterial chemoembolisation (TACE) is an effective palliative treatment for patients who are not eligible for curative treatment. The two main methods for performing TACE are conventional (c-TACE) or with drug eluting beads (DEB-TACE). We sought to compare survival rates and tumour response between patients undergoing c-TACE and DEB-TACE at our centre. MATERIALS AND METHODS: A retrospective cohort study of patients undergoing either treatment was carried out from January 2009 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27566095/benefit-of-patients-with-an-early-and-progressed-state-of-hepatocellular-carcinoma-treated-with-drug-eluting-beads
#14
Nils Rathmann, Maliha Sadick, Bjoern Rathmann, Michael Kostrzewa, Christel Weiss, Stefan O Schoenberg, Steffen J Diehl, Christoph Antoni
AIM: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. MATERIAL AND METHODS: The progression-free interval (PFI), survival and laboratory findings of 46 patients were retrospectively analyzed after DEB TACE. RESULTS: The mean survival interval was 16.93 months. The BCLC A/B group had significantly (p=0.01) longer survival compared to C/D: 20...
September 2016: In Vivo
https://www.readbyqxmd.com/read/27562480/meta-analysis-adjusted-indirect-comparison-of-drug-eluting-bead-transarterial-chemoembolization-versus-90-y-radioembolization-for-hepatocellular-carcinoma
#15
Johannes M Ludwig, Di Zhang, Minzhi Xing, Hyun S Kim
OBJECTIVE: To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ((90)Y)-radioembolization for hepatocellular carcinoma (HCC). METHODS: Studies comparing conventional (c)TACE versus (90)Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus (90)Y-radioembolization was used...
August 25, 2016: European Radiology
https://www.readbyqxmd.com/read/27503585/conventional-versus-drug-eluting-beads-chemoembolization-for-hepatocellular-carcinoma-emphasis-on-the-impact-of-tumor-size
#16
Yong Kang Lee, Kyu Sik Jung, Do Young Kim, Jin Young Choi, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Gyoung Min Kim, Man Deuk Kim, Sung Il Park, Jong Yun Won, Do Yun Lee
BACKGROUND AND AIM: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). PATIENTS AND METHODS: This study retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81...
February 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27436016/liver-and-biliary-damages-following-transarterial-chemoembolization-of-hepatocellular-carcinoma-comparison-between-drug-eluting-beads-and-lipiodol-emulsion
#17
COMPARATIVE STUDY
Arnaud Monier, Boris Guiu, Rafael Duran, Serge Aho, Pierre Bize, Pierre Deltenre, Vincent Dunet, Alban Denys
OBJECTIVES: To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with intermediate-stage hepatocellular carcinoma. METHODS: In this retrospective study, 151 consecutive patients undergoing cTACE or DEB-TACE and MRI 3-6 weeks before and after therapy were included. Toxicity was assessed on imaging (global hepatic damages (GHD), overall biliary injuries, biliary cast, bile duct dilatation, intrahepatic biloma, portal thrombosis), and clinico-biological follow-ups...
April 2017: European Radiology
https://www.readbyqxmd.com/read/27384075/efficacy-and-safety-of-ctace-versus-deb-tace-in-patients-with-hepatocellular-carcinoma-a-meta-analysis
#18
COMPARATIVE STUDY
Jing Huai Zou, Lan Zhang, Zheng Gang Ren, Sheng Long Ye
OBJECTIVE: Conflicting results of the efficacy and safety of conventional transarterial chemo-embolization (cTACE) vs drug-eluting bead (DEB)-TACE have been reported. This meta-analysis aimed to update and re-evaluate the efficacy and safety of cTACE compared with those of DEB-TACE in patients with hepatocellular carcinoma (HCC). METHODS: Literature search was performed by two investigators independently in PubMed, MEDLINE and EMBASE to screen studies published from January 1990 to March 2015...
August 2016: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/27382341/transarterial-chemoembolization-with-drug-eluting-beads-versus-conventional-transarterial-chemoembolization-in-locally-advanced-hepatocellular-carcinoma
#19
Johannes Baur, Christian O Ritter, Christoph-Thomas Germer, Ingo Klein, Ralph Kickuth, Ulrich Steger
PURPOSE: In hepatocellular carcinoma patients with large or multinodal tumors, where curative treatment options are not feasible, transarterial therapies play a major role. Transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) is a promising new approach due to higher intratumoral and lower systemic concentration of the chemotherapeutic agent compared to conventional TACE (cTACE). PATIENTS AND METHODS: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever...
2016: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/27350573/evaluation-of-drug-eluting-beads-versus-conventional-transcatheter-arterial-chemoembolization-in-patients-with-unresectable-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#20
Peng Chen, Peng Yuan, Bo Chen, Jingchang Sun, Hang Shen, Yeben Qian
BACKGROUND AND OBJECTIVES: Transcatheter arterial chemoembolization (TACE) is the first-line treatment for unresectable hepatocellular carcinoma (HCC). It consists of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE). The comparative outcomes of the two methods remain controversial. The study aim to research the optimal TACE strategy for unresectable HCC. METHODS: A systematic search of keywords, including 'HCC' and 'drug-eluting beads' was performed including four electronic databases: PubMed, Embase, China Biological Medicine Database (CBM), and Cochrane library databases from the date of inception to December 25, 2015...
June 24, 2016: Clinics and Research in Hepatology and Gastroenterology
keyword
keyword
109351
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"